Health Canada examines safety of inflammatory bowel disease drug mesalazine in pregnancySafety review could not confirm a link between the use of mesalazine (5-ASA) during pregnancy and birth defects in babies. Fibristal voluntarily withdrawn in Canada due to risk of serious liver injuryAllergan withdraws and recalls uterine fibroid drug ulipristal acetate in Canada due to rare cases of severe liver injury requiring liver transplantation Using PPIs may increase risk of contracting COVID-19: study Previous research has demonstrated that a low level of gastric acid alters the infectivity of SARS-CoV-1—that also appears to be the case for SARS-CoV-2 Lynch syndrome: evidence mounting for ASA prophylaxis, but uncertainties remain Longer-term results of CAPP2 study support use of ASA for prevention of colorectal cancer in patients with Lynch syndrome Webinar on demand: Poop talk to pep talk - Effective probiotics for GI patients Webinar on demand: do not use Hepatitis C antiviral drugs may cause abnormal blood glucose levels Safety review evidence supports a link between direct-acting antivirals and hypoglycemia in patients with diabetes New analysis supports lack of association between alleged PPI-related adverse events and PPI exposure Cross-sectional analysis examines potential sources of bias in studies previously reporting associations between PPI use and adverse effects Are probiotics effective and safe in preventing antibiotic-associated diarrhea in children? Lactobacillus rhamnosus GG and Saccharomyces boulardii have the best evidence, but optimal dose still uncertain New British guidelines on managing inflammatory bowel disease in adults Provide updated guidance on pharmacologic, nonpharmacologic and surgical interventions for ulcerative colitis and Crohn’s disease First Previous 11 12 13 14 15 Next Last
